Peginterferon alfa-2b 50 mcg Injection
RxNorm 284192
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 284192 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: peginterferon alfa-2b 50 mcg Injection.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Clinical Drug (SCD):
Peginterferon alfa-2b 0.05 mg Injection
(Atom ID: 7705955)
Designated preferred name (PT):
Interferon alfa-2b (as peginterferon alfa-2b) 50 microgram powder for solution for injection vial
(Atom ID: 11825590)
Prescribable Name (PSN):
Peginterferon alfa-2b 50 mcg Injection
(Atom ID: 7705963)
Synonym (SY):
Peginterferon alfa-2b 50 mcg Injection
(Atom ID: 7705962)
Full form of descriptor (FN):
Product containing precisely interferon alfa-2b (as peginterferon alfa-2b) 50 microgram/1 vial powder for conventional release solution for injection (clinical drug)
(Atom ID: 11826547)
Patient Education
Peginterferon Alfa-2b (PEG-Intron)
Peginterferon alfa-2b is used alone or in combination with ribavirin (a medication) to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage and who have not been treated with interferon alpha (medication similar to peginterferon alfa-2b) in the past. Peginterferon alfa-2b is in a class of medications called interferons. Peginterferon alpha-2b is a combination of interferon and polyethylene glycol, which helps the interferon stay active in your body for a longer period of time. Peginterferon alpha-2b works by decreasing the amount of hepatitis C virus (HCV) in the body. Peginterferon alfa-2b may not cure hepatitis C or prevent you from developing complications of hepatitis C such as cirrhosis (scarring) of the liver, liver failure, or liver cancer. Peginterferon alfa-2b may not prevent the spread of hepatitis C to other people.
[Learn More]
Peginterferon Alfa-2b Injection (Sylatron)
Peginterferon alfa-2b injection is used in people with malignant melanoma (a life-threatening cancer that begins in certain skin cells) who have had surgery to remove the cancer. This medication is used to reduce the chance that malignant melanoma will come back and must be started within 84 days of the surgery. Peginterferon alfa-2b injection is in a class of medications called interferons. It works by stopping the growth of cancer cells to reduce the chance of malignant melanoma coming back.
[Learn More]
Cancer Chemotherapy
Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.
You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).
NIH: National Cancer Institute
[Learn More]
* Please review the disclaimer below.
